Advancing cancer drug discovery towards more agile development of targeted combination therapies

Future Medicinal Chemistry

Volumn 4, Issue 1, 2012, Pages 87-105

  Carragher, Neil O ^a   Unciti Broceta, Asier ^b   Cameron, David A ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; BORTEZOMIB; CETUXIMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; EVEROLIMUS; FENRETINIDE; FLAVOPIRIDOL; FLUOROURACIL; GEFITINIB; IMATINIB; LAPATINIB; NAVELBINE; PACLITAXEL; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SORAFENIB; SUNITINIB; TRASTUZUMAB; TUMOR MARKER; VANDETANIB;

ACCURACY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CELL VIABILITY; CHEMICAL IMAGING; CHEMICAL PROTEOMIC; CLINICAL TRIAL (TOPIC); CONTENT ANALYSIS; DATA BASE; DIAGNOSTIC TEST; DISEASE MODEL; DRUG DESIGN; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; EXTRACTION; FUNCTIONAL PROTEOMICS; GENETIC ALGORITHM; GENETIC ASSOCIATION; HUMAN; IN VIVO STUDY; LONGITUDINAL STUDY; NONHUMAN; ONCOGENE; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN MICROARRAY; PROTEOMICS; PUBLIC-PRIVATE PARTNERSHIP; REVERSE PHASE PROTEIN ARRAY; REVIEW; TUMOR XENOGRAFT;

ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; DRUG THERAPY, COMBINATION; HUMANS; NEOPLASMS;

EID: 83655198589     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.169     Document Type: Review

References (73)

1. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3(8), 711-715 (2004). (Pubitemid 39173511)
2. Butcher EC. Can cell systems biology rescue drug discovery? Nat. Rev. Drug Discov. 4(6), 461-467 (2005). (Pubitemid 40861988)
3. Sams-Dodd F. Target-based drug discovery: is something wrong? Drug Discov. Today 10(2), 139-147 (2005). (Pubitemid 40247812)
4. Dancey JE, Chen HX. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat. Rev. Drug Discov. 5(8), 649-659 (2006). (Pubitemid 44151603)
5. Stommel JM, Kimmelman AC, Ying H et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318(5848), 287-290 (2007). (Pubitemid 47574858)
6. Yonesaka K, Zejnullahu K, Okamoto I et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci. Transl. Med. 3(99), 99ra86 (2011).
7. Hughes B. Novel agents combined get own guidance. Nat. Biotech. 29, 174 (2011).
8. Ainscow E, Carragher N. Addressing kinetic applications in high content screening. Eur. Pharmaceut. Rev. 5, 44-50 (2008).
9. Carragher NO. Advancing high content analysis towards improving clinical efficacy. Eur. Pharmaceut. Rev. 1, 12-16 (2011).
10. Caie PD, Walls RE, Ingleston-Orme A et al. High-content phenotypic profiling of drug response signatures across distinct cancer cells. Mol. Cancer Ther. 9(6), 1913-1926 (2010).
11. Perlman ZE, Slack MD, Feng Y, Mitchison TJ, Wu LF, Altschuler SJ. Multidimensional drug profiling by automated microscopy. Science 306(5699), 1194-1198 (2004). (Pubitemid 39489001)
12. Tanaka M, Bateman R, Rauh D et al. An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol. 3(5), e128 (2005).
13. Yarrow JC, Perlman ZE, Westwood NJ, Mitchison TJ. A high-throughput cell migration assay using scratch wound healing, a comparison of image-based readout methods. BMC Biotechnol. 4, 21 (2004).
14. Alcock P, Bath C, Blackett C, Simpson PB. High content cell based primary screening for oncology targets - a perspective. Eur. Pharmaceut. Rev. 3, (2010).
15. Bickle M. High-content screening: a new primary screening tool? IDrugs 11(11), 822-826 (2008).
16. Young DW, Bender A, Hoyt J et al. Integrating high-content screening and ligand-target prediction to identify mechanism of action. Nat. Chem. Biol. 4(1), 59-68 (2008). (Pubitemid 350273652)
17. Carragher NO. Profiling distinct mechanisms of tumour invasion for drug discovery: imaging adhesion, signaling and matrix turnover. Clin. Exp. Metastasis 26(4), 381-397 (2009).
18. Isherwood B, Timpson P, McGhee EJ. Live cell in vitro and in vivo imaging applications. Accelerating drug discovery. Pharmaceutics 3(2), 141-170 (2011).
19. Zimmermann GR, Lehar J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today 12(1-2), 34-42 (2007). (Pubitemid 46014485)
20. Chou TC, Talalay P. Generalized equations for the analysis of inhibitions of Michaelis- Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur. J. Biochem. 115(1), 207-216 (1981).
21. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships. The combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27-55 (1984).
22. Borgatti M, Altomare L, Abonnec M et al. Dielectrophoresis-based 'lab-on-a-chip' devices for programmable binding of microspheres to target cells. Int. J. Oncol. 27(6), 1559-1566 (2005).
23. Dittrich PS, Manz A. Lab-on-a-chip: microfluidics in drug discovery. Nat. Rev. Drug Discov. 5(3), 210-218 (2006). (Pubitemid 43336034)
24. Weber L. Applications of genetic algorithms in molecular diversity. Curr. Opin. Chem. Biol. 2(3), 381-385 (1998). (Pubitemid 128423243)
25. Zinner RG, Barrett BL, Popova E et al. Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells. Mol. Cancer Ther. 8(3), 521-532 (2009).
26. Weber L, Walbaum S, Broger C. A genetic algorithm optimizing biological activity of combinatorial compound libraries. Agnew. Chem. Int. Ed. 107, 2453-2454 (1995).
27. Singh J, Ator MA, Jaeger EP. Application of gentic algorithms to combinatorial synthesis: a computational approach to lead identification and lead optimization. J. Am. Chem. Soc. 118, 1669-1676 (1996). (Pubitemid 26092308)
28. Azmi AS, Wang Z, Philip PA, Mohammad RM, Sarkar FH. Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinations. Mol. Cancer Ther. 9(12), 3137-3144 (2010).
29. Iadevaia S, Lu Y, Morales FC, Mills GB, Ram PT. Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Cancer Res. 70(17), 6704-6714 (2010).
30. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov. 2(7), 566-580 (2003). (Pubitemid 37361748)
31. Stoughton RB, Friend SH. How molecular profiling could revolutionize drug discovery. Nat. Rev. Drug Discov. 4(4), 345-350 (2005). (Pubitemid 41130947)
32. Kolch W, Pitt A. Functional proteomics to dissect tyrosine kinase signaling pathways in cancer. Nat. Rev. Cancer 10(9), 618-629 (2010).
33. Voshol H, Ehrat M, Traenkle J, Bertrand E, Van Oostrum J. Antibody-based proteomics: analysis of signaling networks using reverse protein arrays. FEBS J. 276(23), 6871-6879 (2009).
34. Weissenstein U, Schneider MJ, Pawlak M et al. Protein chip based miniaturized assay for the simultaneous quantitative monitoring of cancer biomarkers in tissue extracts. Proteomics 6(5), 1427-1436 (2006).
35. Carey MS, Agarwal R, Gilks B et al. Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. Clin. Cancer Res. 16(10), 2852-2860 (2010).
36. Tibes R, Qiu Y, Lu Y et al. Reverse phase protein array. validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol. Cancer Ther. 5(10), 2512-2521 (2006). (Pubitemid 44650915)
37. Politi K, Pao W. How genetically engineered mouse tumor models provide insights into human cancers. J. Clin. Oncol. 29(16), 2273-2281 (2011).
38. Olive KP, Tuveson DA. The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin. Cancer Res. 12(18), 5277-5287 (2006). (Pubitemid 44497240)
39. Maggi A, Ciana P. Reporter mice and drug discovery and development. Nat. Rev. Drug Discov. 4(3), 249-255 (2005). (Pubitemid 40372558)
40. Ntziachristos V, Bremer C, Weissleder R. Fluorescence imaging with near-infrared light. new technological advances that enable in vivo molecular imaging. Eur. Radiol. 13(1), 195-208 (2003). (Pubitemid 36790510)
41. Weigert R, Sramkova M, Parente L, Amornphimoltham P, Masedunskas A. Intravital microscopy: a novel tool to study cell biology in living animals. Histochem. Cell Biol 133(5), 481-491 (2010).
42. Bullen A. Microscopic imaging techniques for drug discovery. Nat. Rev. Drug Discov. 7(1), 54-67 (2008).
43. Canel M, Serrels A, Anderson KI, Frame MC, Brunton VG. Use of photoactivation and photobleaching to monitor the dynamic regulation of E-cadherin at the plasma membrane. Cell Adh. Migr. 4(4), 491-501 (2010).
44. Reyzer ML, Chaurand P, Angel PM, Caprioli RM. Direct molecular analysis of whole-body animal tissue sections by MALDI imaging mass spectrometry. Methods Mol. Biol. 656, 285-301 (2010).
45. Reyzer ML, Hsieh Y, Ng K, Korfmacher WA, Caprioli RM. Direct analysis of drug candidates in tissue by matrix-assisted laser desorption/ionization mass spectrometry. J. Mass Spectrom. 38(10), 1081-1092 (2003). (Pubitemid 37407703)
46. Baena JR, Lendl B. Raman spectroscopy in chemical bioanalysis. Curr. Opin. Chem. Biol. 8(5), 534-539 (2004). (Pubitemid 39278351)
47. Downes A, Elfick A. Raman spectroscopy and related techniques in biomedicine. Sensors Basel Sensors 10(3), 1871-1889 (2010).
48. Saar BG, Freudiger CW, Reichman J, Stanley CM, Holtom GR, Xie XS. Video-rate molecular imaging in vivo with stimulated Raman scattering. Science 330(6009), 1368-1370 (2010).
49. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1(7), 493-502 (2002).
50. Chen LL, Trent JC, Wu EF et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res. 64(17), 5913-5919 (2004). (Pubitemid 39129383)
51. Cools J, Deangelo DJ, Gotlib J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348(13), 1201-1214 (2003). (Pubitemid 36359296)
52. Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293(5531), 876-880 (2001). (Pubitemid 32743979)
53. Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2(3), e73 (2005).
54. Tamborini E, Bonadiman L, Greco A et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127(1), 294-299 (2004). (Pubitemid 38962296)
55. Xin H, Bernal A, Amato FA et al. High-throughput siRNA-based functional target validation. J. Biomol. Screen. 9(4), 286-293 (2004).
56. Whitehurst AW, Bodemann BO, Cardenas J et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446(7137), 815-819 (2007). (Pubitemid 46582032)
57. Sachse C, Weiss-Haljiti C, Holz C et al. Exploring the full power of combining high throughput RNAi with high content readouts. from target discovery screens to drug modifier studies. In: High Content Screening. Science, Techniques and Applications. Haney SA (Ed.). John Wiley & Sons. 392, 145-168 (2008).
58. Erfle H, Neumann B, Liebel U et al. Reverse transfection on cell arrays for high content screening microscopy. Nat. Protoc. 2(2), 392-399 (2007). (Pubitemid 47040054)
59. Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer 10(2), 130-137 (2010).
60. Hopkins AL, Mason JS, Overington JP. Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol. 16(1), 127-136 (2006). (Pubitemid 43221881)
61. Karaman MW, Herrgard S, Treiber DK et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26(1), 127-132 (2008).
62. Vieth M, Sutherland JJ, Robertson DH, Campbell RM. Kinomics: characterizing the therapeutically validated kinase space. Drug Discov. Today 10(12), 839-846 (2005). (Pubitemid 40824738)
63. Durrant JD, Amaro RE, Xie L et al. A multidimensional strategy to detect polypharmacological targets in the absence of structural and sequence homology. PLoS Comput. Biol. 6(1), e1000648 (2010).
64. Apsel B, Blair JA, Gonzalez B et al. Targeted polypharmacology. discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Biol. 4(11), 691-699 (2008).
65. Learn CA, Hartzell TL, Wikstrand CJ et al. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res 10(9), 3216-3224 (2004). (Pubitemid 38619703)
66. Bhat VT, Caniard AM, Luksch T, Brenk R, Campopiano DJ, Greaney MF. Nucleophilic catalysis of acylhydrazone equilibration for protein-directed dynamic covalent chemistry. Nat. Chem. 2(6), 490-497 (2010).
67. Hunt RA, Otto S. Dynamic combinatorial libraries. new opportunities in systems chemistry. Chem. Commun. (Camb.) 47(3), 847-858 (2011).
68. Ramstrom O, Lehn JM. Drug discovery by dynamic combinatorial libraries. Nat. Rev. Drug Discov. 1(1), 26-36 (2002). (Pubitemid 37361401)
69. Wu Y, Amonkar MM, Sherrill BH et al. Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Ann. Oncol. (2011).
70. Croom KF, Dhillon S. Bevacizumab. A review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer. Drugs 71(16), 2213-2229 (2011).
71. Lai TL, Lavori PW, Shih MC. Adaptive trial designs. Annu. Rev. Pharmacol. Toxicol. doi:10.1146/annurev-pharmtox- 010611-134504 (2011) (Epub ahead of print).
72. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin. Pharmacol. Ther. 86(1), 97-100 (2009).
73. Stead M, Cameron D, Lester N et al. Strengthening clinical cancer research in the United Kingdom. Br. J. Cancer 104(10), 1529-1534 (2011).